News
Evommune launches mid-stage trials for immune-modulating drugs targeting skin conditions, backed by $115M funding and led by ex-Dermira executives.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback